PMID: 9179274May 1, 1997Paper

Bone marrow transplantation in first remission

Leukemia
J M Rowe

Abstract

The allogeneic bone marrow transplant experience for acute myeloid leukemia (AML) is broader than that for acute lymphocytic leukemia (ALL). However, data describing disease-free survival in AML in first remission in the range of 40% to 65% are almost identical to the data from larger studies of ALL in first remission. Similarly, the published allogeneic transplant data for ALL in second remission are comparable to those in the AML experience. The efficacy of autologous stem-cell transplantation for ALL, while promising, remains unproven in first remission, and larger multicenter studies are underway to answer this question. Until prospective randomized trials of bone marrow or peripheral-blood stem-cell purging have been performed, a conclusion that ex vivo bone marrow transplantation is of clinical benefit for any patient with ALL will be impossible. Such studies will be difficult to conduct and, in an autologous setting, should include genetic marking to help determine whether reinfused leukemic cells will lead to relapse.

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Matthias StelljesThomas Büchner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Kamar GodderMary M Horowitz
© 2021 Meta ULC. All rights reserved